Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UreaPRO is a medical food developed by Nephcentric for the dietary management of hyponatremia, specifically in conditions such as Syndrome of Inappropriate Antidiuretic Hormone (SIADH) and Syndrome of Inappropriate Antidiuresis (SIAD). The product contains USP-grade stabilized urea, which acts as an osmotic agent. By increasing the osmotic load in the renal tubules, urea induces osmotic diuresis, facilitating the excretion of excess free water without significant loss of electrolytes like sodium. UreaPRO is available in both an unflavored powder form and a tablet formulation, with each dose providing 15 grams of urea. It is manufactured in the USA under cGMP guidelines and is intended for use under the supervision of a healthcare provider as a lower-cost alternative to other urea-based medical foods.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UreaPRO.